Prospective randomized study of naftopidil combined trospium chloride in the medical treatment of intramural ureteral stone.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006185

Enrollment

Unknown

Registered

2015-03-26

Start date

2015-03-29

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urinary stone

Interventions

A:naftopidil 25 mg once a day / combined trospium chloride placebo 20mg, once a day

B:naftopidil 25 mg once a day / combined trospium chloride 20mg, once a day

C:trospium chloride 20mg, once a day

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: those patients with vesical irritability for intramural ureteral stone (4mm)

Exclusion criteria

Exclusion criteria: Multiple stones, severe incarcerated stones, history of distal ureteral surgery, renal colic for more than 24 h, urinary tract infection, severe hydronephrosis, voiding dysfunction,hypotension, cardiovascular and cerebrovascular diseases,hepatic and renal dysfunction, pregnancy, diabetes and ulcer disease.

Design outcomes

Primary

Measure	Time frame
Pain scores (VAS);	—

Countries

China

Contacts

Public ContactQinglai Tang

tql7807@163.com+86 13912946695

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026